Anixa Biosciences
Anixa is a publicly-traded biotechnology company focused on harnessing the body's immune system in the fight against cancer. Anixa's therapeutic portfolio includes a cancer vaccine technology focused on the immunization against α-Lactalbumin to prevent triple negative breast cancer (TNBC), as well as a cancer immunotherapy program which uses a novel type of CAR-T, known as chimeric endocrine receptor T-cell (CER-T) technology. The company's diagnostic portfolio consists of Cchek™, a liquid biopsy technology for early detection of solid tumors based on the body's immune response to the presence of a malignancy. Anixa continually examines emerging technologies in complementary fields for further development and commercialization.
Tech Stack (13 technologies)
Frequently Asked Questions
What technologies does Anixa Biosciences use?+
Anixa Biosciences uses 13 technologies including Facebook Pixel, FingerprintJS, Google Analytics.
What industry is Anixa Biosciences in?+
Anixa Biosciences operates in the Biotechnology industry.
Where is Anixa Biosciences based?+
Anixa Biosciences is headquartered in United States.
Explore More
Need this data at scale?
Get ready-to-use datasets: companies, technologies, and tech adoption signals across 3M+ websites.
Browse DatasetsData last updated: June 2026